SK Bioscience Co., Ltd. clinical trials

A subsidiary of SK Chemicals Co., Ltd.

The registry lists 12 studies whose lead sponsor is SK Bioscience Co., Ltd.. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 15, 2026.

Status

Completed: 8
Status unknown: 1
Recruiting: 1
Active, not recruiting: 1
Withdrawn: 1

Phase

Phase 1: 6
Phase 3: 5
Phase 2: 5

Where

Korea, Republic of: 7
Philippines: 3
Australia: 2
New Zealand: 2
Thailand: 2
Honduras: 1

Registry sponsor names on this page

SK Bioscience Co., Ltd.12 studies

Something wrong with this grouping? Tell us on the SK Chemicals Co., Ltd. page.

Studies

Recruiting first, then most recently updated. Showing 12 of 12. All SK Chemicals Co., Ltd. studies →

SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 YearsRecruitingNCT07415252Phase 3
Sponsor listed in the registry: SK Bioscience Co., Ltd.
A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy AdultsCompletedNCT06680128Phase 1/2
Sponsor listed in the registry: SK Bioscience Co., Ltd.
A Phase I/II, Dose-finding Study to Assess the Safety, Reactogenicity, and Immunogenicity of a Broadly Protective Sarbecovirus Vaccine (GBP511) in Healthy Adults.Active, not recruitingNCT07280858Phase 1/2
Sponsor listed in the registry: SK Bioscience Co., Ltd.
Immunogenicity and Safety Study of Heterologous Booster Vaccination of a SARS-CoV-2 Recombinant Protein Nanoparticle Vaccine(GBP510) Adjuvanted with AS03 in Adults Aged 18 Years and OlderCompletedNCT05501522Phase 3
Sponsor listed in the registry: SK Bioscience Co., Ltd.
Immunogenicity and Safety Study of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine (GBP510) Adjuvanted With AS03 (COVID-19)CompletedNCT05007951Phase 3
Sponsor listed in the registry: SK Bioscience Co., Ltd.
A Blood Collection Study to Assess the Immunogenicity of Nationally Authorized Homologous COVID-19 Booster Vaccines Among Adult Vaccinees.WithdrawnNCT05710289
Sponsor listed in the registry: SK Bioscience Co., Ltd.
Safety and Immunogenicity of a SARS-CoV-2 Vaccine (NBP2001) in Healthy Adults (COVID-19)CompletedNCT04760743Phase 1
Sponsor listed in the registry: SK Bioscience Co., Ltd.
Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With Aluminum Hydroxide (COVID-19)CompletedNCT04742738Phase 1/2
Sponsor listed in the registry: SK Bioscience Co., Ltd.
Immunogenicity and Safety of NBP607-QIV Compared to Agrippal in Children Aged 6 to 35 MonthsCompletedNCT03704740Phase 3
Sponsor listed in the registry: SK Bioscience Co., Ltd.
Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With or Without AS03 (COVID-19)Status unknownNCT04750343Phase 1/2
Sponsor listed in the registry: SK Bioscience Co., Ltd.
Immunogenicity and Safety Study of NBP615 in Healthy FemaleCompletedNCT04453241Phase 1/2
Sponsor listed in the registry: SK Bioscience Co., Ltd.
Immunogenicity and Safety of NBP608 Compared to Varivax in Healthy Children 12 Months to 12 Years of AgeCompletedNCT03114943Phase 3
Sponsor listed in the registry: SK Bioscience Co., Ltd.